Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis

被引：0
|
作者：
Zhang, Xiaodong
Lu, Ming
Gong, Jifang
Gao, Jing
Wang, Xicheng
Zhang, Xiaotian
Li, Jie
Li, Yan
Li, Jian
Zhou, Jun
Lu, Zhihao
Shen, Lin
机构：
[1] Peking Univ, Sch Oncol, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
[2] Beijing Canc Hosp & Inst, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14604
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.
    Cao, Guochun
    Li, Xiaoyou
    Liu, Delin
    Zhu, Jinghua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.
    Cong, Xiaofeng
    Xu, Zijun
    Liu, Ziling
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 205 - 205
  • [23] NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
    Lv, Huilai
    Tian, Yang
    Li, Zhenhua
    Huang, Chao
    Xu, Yanzhao
    Tian, Ziqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A587 - A587
  • [24] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Zhao, Jia
    Zhang, Simeng
    Guo, Xiaoyu
    Li, Ce
    Yang, Bowen
    Qu, Xiujuan
    Wang, Shuo
    BMC CANCER, 2023, 23 (01)
  • [25] PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
    Jia Zhao
    Simeng Zhang
    Xiaoyu Guo
    Ce li
    Bowen Yang
    Xiujuan Qu
    Shuo Wang
    BMC Cancer, 23
  • [26] Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer:: A pilot study
    Laack, E
    Andritzky, B
    Dürk, H
    Burkholder, I
    Edler, L
    Schuch, G
    Boeters, I
    Görn, M
    Lipp, R
    Horst, H
    Popp, J
    Hossfeld, DK
    ONKOLOGIE, 2005, 28 (12): : 647 - 650
  • [27] Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
    Shi, Yan
    Qin, Rui
    Wang, Zhi-Kuan
    Dai, Guang-Hai
    ONCOTARGETS AND THERAPY, 2013, 6 : 585 - 591
  • [28] First-line paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus
    Zhang, X.
    Shen, L.
    Li, J.
    Li, Y.
    Li, J.
    Jin, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] BIWEEKLY PACLITAXEL AND CISPLATIN - A PHASE-I/II STUDY IN THE FIRST-LINE TREATMENT OF METASTATIC BREAST-CANCER
    OREILLY, SE
    GELMON, KA
    SEMINARS IN ONCOLOGY, 1995, 22 (03) : 109 - 111
  • [30] Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01)
    Li, Yue
    Lin, Lin
    Liu, Jun
    Cai, Xu-Wei
    Zhang, Qin
    Song, Xin-Yun
    Zhao, Sheng-Guang
    Ma, Xiu-Mei
    Fu, Xiao-long
    Yu, Wen
    FUTURE ONCOLOGY, 2023, 19 (34) : 2291 - 2296
12345